Next destination for Watt and Hopkins ,Bioconjugates conference San Francisco June 4,5,6.
Thursday 5th.
12:30
Networking Luncheon in Exhibit and Poster Hall with "Hot Topic" Roundtable Discussions
Moderated by Conference Speakers - Join us during this afternoon's luncheon for informal, moderated hot topic discussions led by your conference speakers. Discuss and debate important industry issues and challenges with other attendees and speakers and make new contacts at the same time.
Delivery Approaches for Intracellular Biologics
Moderator: Paul Watt, Ph.D., Chief Scientific Officer, Phylogica Ltd., Australia
Engineering Therapeutic Proteins for Optimized Plasma Half-Life
Moderator: Arne Skerra, Ph.D., Chief Scientific Officer, XL-protein GmbH, Germany
Peptides as Drugs?
Moderator: Dragan Grabulovski, Ph.D., Chief Scientific Officer, Covagen AG, Switzerland
Assessing and Mitigating Immunogenic Risk: What Factors are Worth Considering?
Moderator: Jonathan Davis, Ph.D., Principal Scientist, Protein Design, Bristol-Myers Squibb
Small is Beautiful - What Half-Life Extension Technology Offers the Best Bang for the Buck?
Moderator: Fredrik Frejd, Ph.D., Chief Scientific Officer, Affibody AB, Sweden
Friday 6th
2:00
Unpublished Data
Efficient Delivery of Biologics into Specific Cell Types Using the Endosome Escape Trap
The efficient delivery of biologics into the cell and out of the endosomes remains a key challenge in accessing the intracellular target landscape. Most conventional CPP's are not cell specific and the vast majority of their cargoes remain trapped within the endosomal compartment. The Endosome Escape Trap enables the specific capture of those rare classes of CPP's which deliver their cargoes to the cytoplasm. Data will be presented showing that certain CPP's from Phylomer libraries can effectively deliver their cargoes which require cytoplasmic delivery for their functional activity
Richard Hopkins, Ph.D., Chief Executive Officer, Phylogica Ltd., Australia
- Forums
- ASX - By Stock
- PYC
- re:tides oligonucleotide & peptide therapeutic
re:tides oligonucleotide & peptide therapeutic, page-11
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PYC (ASX) to my watchlist
(20min delay)
|
|||||
Last
17.5¢ |
Change
-0.005(2.78%) |
Mkt cap ! $839.8M |
Open | High | Low | Value | Volume |
18.0¢ | 18.5¢ | 17.5¢ | $645.9K | 3.602M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 494582 | 17.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 594834 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
12 | 504982 | 0.175 |
6 | 273929 | 0.170 |
12 | 759495 | 0.165 |
7 | 180881 | 0.160 |
6 | 89054 | 0.155 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 579434 | 7 |
0.185 | 1220633 | 11 |
0.190 | 633689 | 15 |
0.195 | 555577 | 6 |
0.200 | 399264 | 7 |
Last trade - 15.30pm 27/09/2024 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |